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Abstract
Background: MicroRNA-381 (miR-381) has been reported to play suppressive or promoting roles in different
malignancies. However, the expression level, biological function, and underlying mechanisms of miR-381 in gastric
cancer remain poorly understood. Our previous study indicated that transmembrane protein 16A (TMEM16A)
contributed to migration and invasion of gastric cancer and predicted poor prognosis. In this study, we found
that miR-381 inhibited the metastasis of gastric cancer through targeting TMEM16A expression.
Methods: MiR-381 expression was analyzed using bioinformatic software on open microarray datasets from the
Gene Expression Omnibus (GEO) and confirmed by quantitative RT-PCR (qRT-PCR) in human gastric cancer tissues
and cell lines. Cell proliferation was investigated using MTT and cell count assays, and cell migration and invasion
abilities were evaluated by transwell assay. Xenograft nude mouse models were used to observe tumor growth
and pulmonary metastasis. Luciferase reporter assay, western blot, enzyme-linked immunosorbent assay (ELISA) and
immunohistochemistry were employed to explore the mechanisms of the effect of miR-381 on gastric cancer cells.
Results: MiR-381 was significantly down-regulated in gastric cancer tissues and cell lines. Low expression of miR-381
was negatively related to lymph node metastasis, advanced tumor stage and poor prognosis. MiR-381 decreased
gastric cancer cell proliferation, migration and invasion in vitro and in vivo. TMEM16A was identified as a direct target
of miR-381 and the expression of miR-381 was inversely correlated with TMEM16A expression in gastric cancer tissues.
Combination analysis of miR-381 and TMEM16A revealed the improved prognostic accuracy for gastric cancer patients.
Moreover, miR-381 inhibited TGF-β signaling pathway and down-regulated epithelial–mesenchymal transition (EMT)
phenotype partially by mediating TMEM16A.
Conclusions: MiR-381 may function as a tumor suppressor by directly targeting TMEM16A and regulating TGF-β
pathway and EMT process in the development of progression of gastric cancer. MiR-381/TMEM16A may be a novel
therapeutic candidate target in gastric cancer treatment.
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Background
Gastric cancer is the leading cause of cancer-related death
worldwide, especially in China [1, 2]. Despite the treat-
ments have been improved dramatically in recent years,
invasion and metastasis, the major causes of gastric cancer
related relapse and death, greatly impeded the treatment
efficiency [3, 4]. However, the molecular mechanism
underlying the invasion and migration of gastric cancer is
still limited.
MicroRNA (miRNAs), a class of endogenous non-
coding small RNAs, negatively regulate gene expression
by binding to the 3′-untranslated regions (3′-UTR) of
their target mRNAs, resulting in the degradation or
translational repression [5, 6]. Emerging evidence has
demonstrated that miRNAs are dysregulated in various
human cancers and are associated with tumorigenic pro-
cesses including cell proliferation, apoptosis, angiogenesis
and invasion via their interaction with oncogenes and
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anti-oncogenes [5, 7]. Therefore, identifying specific
miRNAs that play important roles in tumorigenesis
would be beneficial for cancer diagnosis, prognosis,
and therapy [8].
MicroRNA-381 (miR-381), located in a cluster within
the 14q32.31 chromosomal region where miRNAs have
been revealed to regulate cellular behaviors that are key
to tumorigenicity [9, 10]. The expression of miR-381 is
dysregulated in various cancer types. In lung adenocarcin-
oma [11], epithelial ovarian cancer [12], colon cancer
[13, 14], breast cancer [15], hepatocellular carcinoma
[16] and pituitary tumor [17], miR-381 is down-regulated
and suppresses the malignancy of these tumors, suggest-
ing that miR-381 may have potential roles as a tumor-
suppressor miRNA. On the contrary, the expression of
miR-381 is elevated in glioma [18, 19], synovial sarcoma
[20], epitheliod sarcoma [21] and osteosarcoma [22], and
silencing miR-381 inhibits the glioma growth [18] or
increases the sensitivity of osteosarcoma cells to chemo-
therapeutic drugs [22]. Therefore, the functional roles of
miR-381 in human cancers varied between different
cancer types. However, little is known about the roles of
miR-381 in the development of gastric cancer and the mo-
lecular mechanisms by which miR-381 exerts its functions.
TMEM16A (Transmembrane protein 16A), also known
as ANO1, DOG1 or TAOS2, is a calcium-activated chlor-
ide channel [23] and plays a vital role in cell physiological
behaviours, such as sensory transduction, epithelial secre-
tion, smooth muscle contraction [24–26]. Accumulating
evidence shows that TMEM16A is a candidate oncogene
which plays crucial roles in the cellular events critical in
tumorigenesis, including proliferation, apoptosis and me-
tastasis [27–30]. Our previous study also reported that
TMEM16A was highly expressed in gastric cancer and
contributed to invasion and migration through transform-
ing growth factor beta (TGF-β) signaling pathway, and
TMEM16A overexpression was more pervasive than gene
amplification in gastric cancer [31]. However, the up-
stream molecules regulating TMEM16A expression in
cancer cells remain unclear. Recently, Mokutani et al. [32]
demonstrates that ANO1 (TMEM16A) is a direct target
of miR-132, and miR-132 overexpression markedly sup-
presses ANO1 expression level in colorectal cancer, sug-
gesting that microRNAs may be involved in modulating
TMEM16A expression.
In this study, we investigated the biological function
and the molecular mechanism of miR-381 in gastric
cancer. MiR-381 was notably decreased in gastric cancer
clinical specimens and cell lines, and decreased expression
of miR-381 was associated with adverse clinicopathologi-
cal features and poor prognosis of gastric cancer patients.
Functionally, miR-381 was found to inhibit the prolifera-
tion, migration and invasion of gastric cancer cells both in
vitro and in vivo. Mechanically, miR-381 could suppress
TGF-β signaling pathway and down-regulate EMT pheno-
type by targeting TMEM16A. Our findings elucidated the
detailed roles of miR-381 in gastric cancer and further
contribute to offering the effective therapeutic targets for
the treatment of gastric cancer.
Methods
MicroRNA expression profile data from Gene Expression
Omnibus (GEO)
MicroRNA array expression profile data GSE26595 and
GSE28700 were downloaded from open Gene Expression
Omnibus (GEO) database (https://www.ncbi.nlm.nih.gov/
geo/), which contained 60 primary gastric cancer tissues
and 8 surrounding non-cancer tissues, 22 gastric cancer
tissues and paired normal tissues, respectively. These
microRNA array expression data were analyzed by the
Qlucore Omics Explorer (QOE 3.1) bioinformatics soft-
ware (http://www.qlucore.com/). The QOE offers state-of-
the-art mathematical and statistical methods, and its main
features are the ease of use and speed with which datasets
can be analyzed and explored [33, 34]. The miR-381
expression level were explored in primary gastric cancer
tissues and paired non-tumor tissues.
Patients and tissue specimens
Paraffin-embedded pathological specimens from 103
primary gastric cancers and paired adjacent non-tumor
tissues were obtained from the archives of the Department
of pathology, the First Affiliated Hospital of Sun Yat-Sen
University, Guangzhou, China, between July 2006 and
June 2011. None had received preoperative radiotherapy
or chemotherapy before surgery. Postsurgical chemother-
apies were performed depending on the severity of the
disease and according to the National Comprehensive
Cancer Network (NCCN) guidelines. The clinical and
pathological parameters are shown in Table 1. The pa-
tients’ TNM stage was defined according to AJCC staging
system for gastric cancer [35]. All the samples were col-
lected with patient’s informed consent after approval from
the Institute Research Medical Ethics Committee of the
First Affiated Hospital, Sun Yat-sen University.
Cell lines and transfection
Six human gastric adenocarcinoma cell lines, AGS,
MKN-45, MKN-28, SGC-7901, BGC-823, MGC-803 and
one human gastric epithelial cell line GES-1, were used
in this study. All cell lines were obtained from Institute
of Biochemistry and Cell Biology at the Chinese Acad-
emy of Sciences (Shanghai, China), and were grown in
F-12 k (ATCC) supplemented with 10% fetal bovine
serum and 1% penicillin-streptomycin at 37 °C with hu-
midified 5% CO2.
2 × 105 cells were plated in 6-well plates and transfected
with 100 nmol/L miRNAs employing Lipofectamine
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RNAiMAX Transfection Reagent (Invitrogen) according
to the manufacturer’s protocol. The agomiR miR-381
(agomiR-381), antagomiR miR-381 (antagomiR-381)
and their negative control (Con) Oligonucleotides were
purchased from Shanghai GenePharma Co. Ltd. The
coding sequences TMEM16A were amplified by PCR
and inserted into pcDNA3.1 vector (Invitrogen) to gen-
erate TMEM16A overexpression vectors.
RNA extract and quantitative real-time PCR
Total RNA was extracted from gastric cancer cell lines,
tumor tissues and paired adjacent non-tumor tissues using
Trizol Reagent (In vitrogen, USA) according to the manu-
facturer’s instructions. RNA was reverse transcribed to
cDNA by using One Step PrimeScript miRNA cDNA Syn-
thesis Kit (TaKaRa), and quantitative real time PCR was
performed using SYBR Premix Ex Taq II (TaKaRa).
MiRNA expression levels were normalized against the en-
dogenous U6 small nuclear RNA (U6 snRN A) control.
The relative expression level of miR-381 in each matched
cancer and adjacent non- tumor tissue was calculated by
the 2-ΔΔCT method. The sequences of the PCR primers
were as follows: miR-381 forward, 5′-AGTCTATACA
AGGGCAAGCTCTC-3′, and reverse primer was Uni-
miR qPCR primer (TaKaRa); U6 forward, 5′-CTCGC
TTCGGCAGCACA-3′ and reverse, 5′-AACGCTTCAC
GAATTTGCGT -3′; TMEM16A forward, 5′-ATTTCAC
CAATCTTGTCTCCATCA-3′, and reverse, 5′-TGATA
ACTCCAAGAACGATTGCA-3′; GAPDH forward, 5′CT
CCTCCTGTTC GACAGTCAGC-3′, and reverse 5′-CC
CAATACGACCAAATCCGTT-3′.
In vitro cell proliferation assay
Cell count and MTT assay was used to determine the cell
proliferation capacity. For cell count, cells were serum free
for 24 h. Then cells were trypsinized and equal number
(2 × 105) of cells from each group was plated into 6-well
culture plates in complete culture medium for 0, 1, 2, 3,
and 4 days. For MTT assay, cells were serum free for 24 h.
Then cells were plated in 96-well plates at 2000 per well
in a final volume of 100 μl. Then at 0, 1, 2, 3, and 4 days,
25 μl of MTT stock solution was added to each well and
incubated for 4 h. The absorbance was measured at
570 nm. The assays were performed in triplicates.
In vitro cell migration and invasion assays
Cell migration and invasion assays were performed using
Transwell chambers with or without a Matrigel (BD
Biosciences) coating. Briefly, 2 × 104 transfected cells in
serum-free DMEM medium were placed into the upper
compartment of the chamber. Medium containing 10%
FBS were added to the lower chamber to serve as
chemoattractant. After incubation for 48 h in a humidi-
fied atmosphere of 5% CO2 at 37 °C, the cells on the
upper surface of the filters were removed from the top
well with a cotton swab, while the cells migrated or in-
vaded into the the lower surface of the filters were fixed
with 70% methanol for 30 min and stained with 0.2%
crystal violet for 10 min. Photographs of 5 randomly se-
lected fileds of the fixed cells were taken and counted
under a light microscope at the magnification of 100×.
In vivo tumor formation and metastasis assays
Animal experiments were performed in compliance
with the guidelines for the Welfare of Experimental
Animals in Sun Yat-sen University. For in vivo tumori-
genicity assay, briefly, 5 × 105 agomiR-381 and negative
control transfected cells were subcutaneously into the
right flank of each nude mouse, of 4- to 5-week old nude
mice (5 mice per group). Tumor volume was measured
every 3 days over a 3-week period (formula: tumor volume
(mm3) = length × width2 × 0.5). For in vivo metastasis
assay, briefly, 5 × 105 cells transfected with agomiR-381 or
negative control were intravenously injected through the
tail vein of 4- to 5-week-old nude mice (5 mice per group).
After 4 weeks, the mice were euthanized and the number
of metastases per lung was determined under a dissecting
microscope. The lungs were excised and embedded in par-
affin. Then, hematoxylin and eosin (H&E) staining was
performed to affirm the presence of tumors.
Table 1 Correlation of miR-381 expression with clinicopathological
parameters
Variable All Cases miR-381 expression P valuea
High Low
Gender
Male 71 43 28 0.829
Female 32 18 14
Age at surgery
<57b 59 34 25 0.840
≥57 44 27 17
Tumor size
≥5 cm 44 24 20 0.425
<5 cm 59 37 22
Histological type
Intestinal 88 51 37 0.583
Diffuse 15 10 5
TNM
I + II 54 43 11 0.000
III + IV 49 18 31
Lymph node metastases
Present 59 27 32 0.002
Absent 44 34 10
aChi square test; bmedian age
The entries in boldface with significance as P < 0.05
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Luciferase reporter assay
The wild-type TMEM16A-3′UTR (WT) and mutant
TMEM16A-3′UTR (MUT) containing the putative
binding site of miR-381 were chemically synthesized
and cloned into the downstream of the firefly luciferase
gene in a pGL3-promoter vector (Ambion). The gastric
cancer cells were seeded in 24-well plates for 24 h, and
then were co-transfected with wide-type or mutant-
type TMEM16A vector, and agomiR-381 or negative
control. After 48 h, cells were harvested, the activities
of both firefly and Renilla luciferases in cell lysates were
measured using the Dual Luciferase Reporter Assay
System (Promega). Renilla luciferase was used for
normalization.
Western blot assay
Cells were collected and lysed with the RIPA buffer
containing protease inhibitor. Protein concentration was
determined by the Bradford method with bovine serum
albumin as the control. Equal amounts of protein lysates
(30 μg each lane) were separated 10% SDS-PAGE gel
and then electrotransferred to polyvinylidene difloride
membranes. The membranes were then blocked and
incubated with primary antibodies against TMEM16A
(1:500, Abcam), β-actin antibody (1:1000, Santa Cruz)
respectively, for 2 h at room temperature, and then
incubated with appropriate horseradish peroxidaseconju-
gated secondary antibodies (1:1000, Cell Signaling Tech-
nology) for 1 h at room temperature. Final detection was
carried out with LumiGLO chemiluminescent reagent
(New England Biolabs) as described by the manufacturer.
The densities of target bands was accurately determined
by the computer-aided 1-D gel analysis system.
Immunohistochemistry (IHC)
The paraffin-embedded tissue sections (4 μm in thick-
ness) were subjected to IHC assays as previously de-
scribed [31].
Enzyme-linked Immunosorbent Assay (ELISA)
Sandwich ELISA using Quantikine human TGF-β1 im-
munoassay and TGF-β2 immunoassays (R&D Systems)
to detect TGF-β1 and TGF-β2 levels as described
previously [31].
Statistical analysis
Statistical analysis was performed using SPSS standard
version 19.0 and GraphPad Prism 5. Student’s t test was
used to compare the levels of cellular proliferation,
migration and invasion between different groups. Chi-
square test was used to compare the levels of miR-381
expression and various clinicopathological parameters
of gastric cancer patients. Survival curves calculation and
overall survival (OS)/progression-free survival (PFS) curve
plotting used the Kaplan-Meier method, and the Log-
Rank test was applied to compare the distribution be-
tween patient subsets. P < 0.05 was set to be statistically
significant.
Results
MiR-381 is decreased in gastric cancer tissues and cells
To explore the expression pattern of miR-381 in gastric
cancer, we first downloaded microRNA array expres-
sion profile datasets GSE26595 and GSE28700 from the
open Gene Expression Omnibus (GEO) database.
QOE3.1 software was used to analyze the expression of
miR-381 in gastric cancer tissues and adjacent non-
tumor tissues. The results showed that miR-381 was
significantly down-regulated in gastric cancer tissues
compared with adjacent non-tumor tissues in both
GSE26595 and GSE28700 (Fig. 1a) (P < 0.01, P < 0.01,
respectively). To further validate the findings, we de-
tected miR-381 in 103 paraffin embedded gastric cancer
tissues and paired adjacent non-tumor tissues through
qRT-PCR. As expected, down-regulation of miR-381
was observed in 81 (78.6%) cases of gastric cancer tis-
sues, which was markedly lower than that in adjacent
non-tumor tissues (Fig. 1b and c). In cell level, miR-381
expression was decreased in AGS, SGC-7901, BGC-
823, MKN-45 cell lines than that in the normal gastric
epithelial cell line GES-1 (Fig. 1d). All the above results
indicated that miR-381 was down-regulated in gastric
cancer.
Down-regulation of miR-381 is associated with adverse
clinicopathological features and poor prognosis
We next examined the potential clinical significance
of miR-381 in gastric cancer. Based on relative expres-
sion in cancer/adjacent non-tumor < or >0.5, the 103
gastric cancer cases were divided into two groups: the
miR-381 high expression group (n = 41) and the miR-
381 low expression (n = 62). The correlation between
miR-381 expression and clinicopathological character-
istics was shown in Table 1. Low miR-381 expression
was positively associated with present lymph node me-
tastasis, advanced tumor stage (P = 0.002, P = 0.000,
respectively). However, the expression level of miR-
381 was not significantly associated with gender, age
at surgery, tumor size, histological type.
Kaplan–Meier survival analyses showed that gastric
cancer patients with low miR-381 expression had a
significantly shorter overall survival and progression-
free survival time than those patients with high miR-381
expression (P = 0.024, P = 0.037, respectively) (Fig. 1e
and f ). However, multivariate cox regression analysis
failed to identify miR-381 expression as an independent
prognostic factor for gastric cancer patients (data not
shown). Based on these findings, we speculated that
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Fig. 1 (See legend on next page.)
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miR-381 might play a crucial role in gastric cancer
development.
MiR-381 inhibits gastric cancer cell proliferation, invasion
and migration in vitro
To investigate the biological function of miR-381 in
development and progression of gastric cancer, we per-
formed gain- and loss- function experiments through
transfection with agomiR-381 and antagomiR-381. First,
AGS and BGC-823 cells, which were lower expression of
miR-381, were transfected with agomiR-381. Ectopic
expression of miR-381 of the two gastric cancer cell
lines was confirmed by qRT-PCR after transfection
(Additional file 1: Figure S1). Cell count and MTT assay
showed that the cancer cells proliferation was dramatic-
ally inhibited in miR-381 overexpression group com-
pared to that in the negative control group (Fig. 2a and b).
In order to investigate the role of miR-381 in cell migra-
tion and invasion, transwell chamber assay was performed
in gastric cancer cells. We found ectopic expression of
miR-381 in AGS and BGC-823 cells could significantly in-
hibit cell invasion and migration. The number of invasive
and migrated cells in the miR-381 ectopic expression
group was notably decreased compared with the nega-
tive control group in two gastric cancer cell lines
(Fig. 2c and d). On the other hand, we transfected
MKN-28 and SGC-7901 which expressed relative
higher levels of miR-381 using antagomiR-381. QTR-
PCR was used to comfirmed the decrease expression of
miR-381 (Additional file 2: Figure S2). As expected,
inhibition of miR-381 markedly faciliated the prolifera-
tion, migration and invasion of MKN-28 and SGC-7901
cells (Fig. 2e-h). These results proved that miR-381 inhib-
ited proliferation, invasion and migration of gastric cancer
cells in vitro.
Overexpression of miR-381 inhibits tumor growth and
metastasis in vivo
Given that miR-381 inhibited the proliferation, migra-
tion and invasion of gastric cancer cell in vitro, we fur-
ther detected the influence of miR-381 on tumor
growth and metastasis in vivo. The in vivo role of miR-
381 in tumor growth was evaluated by xenograft tumor
formation in athymic nude mice. The tumor growth
curve indicated that tumors in miR-381 overexpression
group grew much more slowly than tumors in the
negative control group (Fig. 3a). Moreover, overexpres-
sion of miR-381 can lead to significantly reduced tumor
weight to the negative control group mice (Fig. 3b). To
evaluate the in vivo effects of miR-381 on tumor metas-
tasis, nude mice were injected intravenously in the tail
vein with miR-381 overexpression or negative control
gastric cancer cells respectively. Histological analysis
revealed that the number of metastatic nodules was
significantly reduced in the lung of mice injected with
miR-381 overexpression cells compared to that with
negative control cells (Fig. 3c). Taken together, these
data indicated that miR-381 inhibited growth and me-
tastasis of gastric cancer cells in vivo.
TMEM16A is a direct target of miR-381
According to bioinformatic databases (miRanda), there
was a binding site of miR-381 in TMEM16A 3′-UTR
(Fig. 4a). To validate that TMEM16A was a direct target
gene of miR-381, luciferase assay were performed. We
initially constructed two types of plasmids containing
the luciferase reporting gene and wild-type or mutant
TMEM16A 3′UTR (Fig. 4a) and cotransfected agomiR-
381 into AGS and BGC-823 cells. Results showed that
miR-381 overexpression significantly reduced wide-type
TMEM16A luciferase activity, while had no inhibition
effect on the mutant-type TMEM16A luciferase activity
in AGS and BGC-823 cells (Fig. 4b). Next, qRT-PCR and
western blot assay was performed to investigate whether
the mRNA and protein expression of TMEM16A was in-
fluenced. Compared to the negative control group, both
the TMEM16A mRNA and protein level was markedly
down-regulated in miR-381 overexpression group (Fig. 4c
and d). These results indicated that TMEM16A was a
direct target of miR-381.
To further confirm that TMEM16A was negatively
regulated by miR-381 in gastric cancer, we examined the
expression of TMEM16A protein using immunohisto-
chemistry in gastric cancer tissues. Compared with that
in tissues of low expression of miR-381, the expression
of TMEM16A potein was significantly lower in tissues
with a high level of miR-381 (Fig. 4e). Moreover, the
expression of miR-381 was inversely related to the level
of TMEM16A expression in gastric cancer tissues
(Fig. 4f, Table 2). Then, according to the expression level
(See figure on previous page.)
Fig. 1 MiR-381 is low-expressed in gastric cancer tissues and cell lines. a Bioinformatic analysis of the level of miR-381 expression of GSE26595
and GSE28700 datasets showed that miR-381 was significantly lower in gastric cancer tumors (T) than in non-tumor tissues (N). (P < 0.01, P < 0.01,
respectively); b QRT-PCR analysis of miR-381 expression in 103 pairs gastric cancer tissues and their corresponding adjacent non-tumor tissues.
The expression of miRNA was normalized to U6 snRNA; c Relative miR-381 expression levels in gastric cancer tissues and adjacent non-tumor
tissues. **P < 0.01; d QRT-PCR analysis of miR-381 expression in gastric cancer cell lines (AGS, MKN-45, MKN-28, SGC-7901, BGC-823, MGC-803)
and gastric epithelial cell line (GES-1). *P < 0.05, **P < 0.01; e, f Overall survival and progression-free survival were compared between gastric
cancer patients with low expression level of miR-381 and those with high level of miR-381
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of miR-381 mRNA and TMEM16A protein, we diveded
103 gastric cancers into four groups, miR-381 low ex-
pression and TMEM16A high expression (miR-381-/
TMEM16A+), miR-381 low expression and TMEM16A
low expression (miR-381-/TMEM16A-), miR-381 high
expression and TMEM16A high expression (miR-381
+/TMEM16A+), miR-381 high expression and
TMEM16A low expression (miR-381+/TMEM16A-),
and their association with lymph node metastasis and
overall survival (OS) was analyzed. The results showed
that miR-381-/TMEM16A+ group was associated with
a significantly higher metastasis rate (Fig. 4g). More-
over, miR-381-/TMEM16A+ predicted poor prognosis,
while miR-381+/TMEM16A- indicated relative favor-
able prognosis (Fig. 4h). These results suggested that
the increase of TMEM16A expression by inhibition of
miR-381 has a critical role in promoting gastric cancer
invasion and metastasis.
Fig. 2 MiR-381 suppresses gastric cancer proliferation, migration and invasion in vitro. a, b Cell count and MTT assay analysis were used to
evaluate the proliferation of gastric cancer cells (AGS and BGC-823) after transfection with the miR-381 agomiR (agomiR-381) or negative control
(Con). **P < 0.01. c, d Transwell assay was performed to detect the ability of migration and invasion of agomiR-381 transfected gastric cancer cells
and their negative control. **P < 0.01. (e, f) Cell count and MTT assay analysis were used to evaluate the proliferation of gastric cancer cells (MKN-28
and SGC-7901) after transfection with the miR-381 antagomiR (antagomiR-381) or negative control (Con). *P < 0.05, **P < 0.01. g, h Transwell assay
was performed to detect the ability of migration and invasion of antagomiR-381 transfected gastric cancer cells and their negative control. **P < 0.01
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TMEM16A mediates the functional effects of miR-381 on
migration and invasion in gastric cancer cells
After indicating that miR-381 suppressed gastric cancer
cell invasion in vitro and in vivo and identifying
TMEM16A as a direct target of miR-381, we next
focused on whether TMEM16A could mediate the bio-
logical function of miR-381 in gastric cancer. First, we
transduced agomiR-381 or negative control and overex-
pression of TMEM16A plasmids. We found that ectopic
expression of miR-381 reduced the TMEM16A protein ex-
pression, while co-transfection of TMEM16A overexpres-
sion TMEM16A plasmids could recover the TMEM16A
expression (Fig. 5a). Furthermore, co-transfection of
TMEM16A overexpression reverted the suppressive ef-
fects of miR-381 overexpression on the migration and in-
vasion of gastric cancer cells (Fig. 5b and c). However,
supplement of TMEM16A-overexpressing did not reverse
the inhibition of gastric cancer cell proliferation induced
by the miR-381 overexpression (Fig. 5d and e). It was con-
sistent with our previous finding that knockdown of
TMEM16A did not affect proliferation of gastric cancer
cells, suggesting that miR-381 stimulated gastric cancer
cell proliferation through any other targets rather than
TMEM16A.
MiR-381 suppresses TGF-β signaling pathway and down-
regulates EMT phenotypes
Our previous study found that TMEM16A contributed
to gastric cancer cell invasion through promoting TGF-
βs secretion [31]. Therefore, we explored whether miR-
381 suppressed TGF-βs signaling pathway via targeting
TMEM16A. First, cell supernatants were gathered and
concentrations of TGF-β1 and TGF-β2 were measured
by sandwich ELISA. Compared to negative control, miR-
381 overexpression significantly reduced TGF-β1 and
TGF-β2 levels, while co-transfection of TMEM16A over-
expression could rescue the down-regulation of TGF-β1
and TGF-β2 levels partially (Fig. 6a). We previously
reported that TMEM16A promoted TGF-βs secretion
rather than synthesis, hence, we further investigated the
mRNA level of TGF-βs in AGS and BGC-823 cells.
Surprisingly, miR-381 overexpression could significantly
abolish the mRNA expression of TGF-β1 and TGF-β2.
However, overexpression of TMEM16A did not rescue
the mRNA expression of TGF-βs (Fig. 6b). In protein
level, TGF-β1 and TGF-β2 were significantly de-
creased in miR-381 overexpression group compared
with the negative control group. While co-transfection
of TMEM16A expression, TGF-β1 and TGF-β2 pro-
tein expression were further decreased (Fig. 6c). These
data indicated that miR-381 reduced TGF-βs secretion
partially through targeting TMEM16A, and miR-381
inhibited TGF-βs synthesis via other pathways rather
than targeting TMEM16A. To further confirm TGF-β
was involved in the suppressive effect of miR-381 on
migration and invasion, recombinant purified TGF-β
was added to miR-381 overexpression group. Supple-
ment of TGF-β significantly reverted the ability of in-
vade and migrate in gastric cancer cell which were
inhibited by miR-381 overexpression (Fig. 6d and e).
Based on the fact that TGF-β can induce epithelial–
mesenchymal transition (EMT) [36], and our previous
Fig. 3 Overexpression of miR-381 inhibits gastric cancer growth and metastasis in vivo. a Growth curve of tumors in nude mice. Tumor diameters
were measured every 3 days. **P < 0.01. b The average weight of tumors in nude mice.**P < 0.01. c Representative HE staining of lung metastasis
of agomiR-381 and negative control group. **P < 0.01. Red arrows show the position of lung metastasis
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finding that TMEM16A suppressed E-Cadherin expres-
sion through promoting TGF-β secretion [31], we
further detected the effect of miR-381 on EMT related
markers. Our results showed that miR-381 overexpres-
sion could notably down-regulate mesenchymal markers,
vimentin, fibronectin, N-Cadherin, but up-regulated
epithelial marker E-Cadherin, and enforced TMEM16A
expression could partially rescue the expression of these
EMT markers (Fig. 6f ). These data demonstrated that
miR-381 could inhibit TGF-β signaling pathway and
Fig. 4 TMEM16A is a direct target of miR-381 in gastric cancer cells. a MiR-381 and its putative binding sequence in the wild-type and mutant 3′-UTR
of TMEM16A. b Overexpression of miR-381 significantly decreased the luciferase activity that carried wild type (WT) but not mutant type (MUT) 3′-UTR
of TMEM16A in gastric cancer cells. **P < 0.01. c, d Overexpression of miR-381 markedly suppressed the mRNA and protein levels of TMEM16A in
gastric cancer cells. **P < 0.01. e Representative immunohistochemistry (IHC) staining of TMEM16A in high or low miR-381 expression gastric cancer
tissues. f MiR-381 expression was inversely related to TMEM16A expression in gastric cancer tissues. **P < 0.01. g The correlation between miR-381/
TMEM16A co-expression and the percentage of metastatic lymph nodes, P < 0.05. h Overall survival of gastric cancer patients. Patient groups were
separated based on expression status of miR-381 and TMEM16A
Table 2 The relationship between miR-381 expression and







Low (%) High (%)
miR-381 Low (%) 62 9 (14.5%) 53 (85.5%) 0.005 −0.280
High (%) 41 16 (39.1%) 25 (60.9%)
Cao et al. Journal of Experimental & Clinical Cancer Research  (2017) 36:29 Page 9 of 16
Fig. 5 (See legend on next page.)
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down-regulate EMT phenotype partially through target-
ing TMEM16A, and miR-381/TMEM16A/TGF-β/EMT
axis contributed to the migration and invasion of gastric
cancer cells.
Discussion
Numbers of miRNAs have been identified to be involved
in a variety of tumorigenic processes, including cell pro-
liferation, apoptosis, migration and invasion. In this
study, the oncological significance of miR-381 in gastric
cancer was investigated and it was demonstrated that:
(1) miR-381 expression was significantly decreased in
gastric cancer tissues and cell lines, (2) low expression of
miR-381 was associated with lymph node metastasis,
advanced tumor stage and poor prognosis of gastric can-
cer patients, (3) down-regulation of miR-381 contributed
to gastric cancer proliferation and metastasis in vitro
and in vivo, (4) TMEM16A was a direct target of miR-
381 and they were inversely correlated with each other
in clinical gastric cancer specimens, (5) TMEM16A me-
diated the functional effects of miR-381 on migration
and invasion rather than proliferation of gastric cancer,
(6) miR-381 acted as a suppressor gene miRNA par-
tially through suppressing TGF-β signaling pathway
and EMT.
MiR-381 was mapped to the chromosomal 14q32.31
locus where existed a cluster of miRNAs, such as miR-
154 and miR-377, which have been reported to act as a
tumor suppressor in several cancers [9]. For example,
miR-154 was down-regulated in breast cancer and
inhibited growth and invasion [37] and suppressed hepa-
tocellular carcinoma tumorigenic and metastatic potential
in vitro and in vivo [38]. MiR-377 overexpression reduced
cell proliferation and suppressed invasion of osteosarcoma
cells [39] and impeded the ability of clear cell renal cell
carcinoma cells to proliferate, migrate and invade [40].
With regard to miR-381, it has been widely reported as a
potential tumor suppressor miRNA in previous studies.
Up-regulation of miR-381 expression could abrogated
cancer cells proliferation, invasion and migration in
various solid tumors [11–17]. Moreover, miR-381 in-
creased the sensitivity of renal cancer cells to 5-
fluorouracil (5-FU) [41] and modulated the multidrug
resistance (MDR) phenotype in leukemia cells and in-
creased their drug uptake [42]. Consistent with these
studies, the present study found that miR-381 was
markedly decreased in gastric cancer, and miR-381
expression prohibited gastric cancer cells proliferation,
invasion and migration in vitro and in vivo and pre-
dicted favorable prognosis. However, the potential role
of miR-381 as a onco-miRNA also has been uncovered.
Tang et al. [18, 19] showed that miR-381 expression
was increased in glioma and promoted tumor cell
pathological malignant progression. Li et al. [22] found
a high expression of miR-381 in osteosarcoma and the
association with an inferior prognosis, and suppression
of miR-381 expression increased the sensitivity of
osteosarcoma cells to cisplatin. In fact, there were many
miRNAs like miR-381 have been demonstrated to play
both tumor-suppressing and tumor-promoting roles
that depend on the cancer types. For instance, miR-377,
which was also located in 14q32.31, unlike the role in
osteosarcoma [39] and renal cell carcinoma [40], in-
creased in gastric cancer and promoted cell prolifera-
tion [43]. MiR-204 has been demonstrated to have a
dual function as a tumor-suppressive miRNA and/or an
oncomiR in different cancers [44–46]. Even in the same
cancer type, miR-204 also had a dual regulatory func-
tion in different cancer subtypes. In prostate cancer,
miR-204 acted as an oncomiR in neuroendocrine-like
prostate cancer cells but as a tumor suppressor in pros-
tatic adenocarcinoma cells [47]. These findings showed
the complexity of miRNAs including miR-381 in can-
cers, more than that, suggesting that therapies targeting
miRNAs must consider their potential dual role in
cancers.
In regard to the upstream regulatory mechanisms of
miR-381, Liang et al. [17] reported that P53 binds to
the promoter of miR-381, activating miR-381 transcrip-
tion and inducing its expression. Hou et al.[48] found
that the expression levels of transcriptional factors Sox9
and Runx2 are positively correlated with transcription of
miR-381, indicating they may regulate expression of miR-
381. However, the regulation of miR-381 has not been
thoroughly studied. In deed, the regulation mechanisms
of microRNA are very complicated, in that microRNA
can be regulated at different levels including the pre-
transcriptional, transcriptional, and post-transcriptional
level [49, 50]. Such as DNA copy number variation,
DNA methylation, histone modification, transcription
factor (TF) and post-transcripitonal modification,
which were involved in the regulation of microRNA
(See figure on previous page.)
Fig. 5 TMEM16A mediates the effects of miR-381 on migration and invasion in gastric cancer cells. Gastric cancer cells tranfected with agomiR-381
and negative control, together with blank vector or TMEM16A overexpression plasmid. a Western blot analysis showed that ectopic expression of miR-
381 reduced the TMEM16A protein expression, while co-transfection of TMEM16A overexpression TMEM16A plasmids could recover the TMEM16A
expression. **P < 0.01. b, c Co-transfection of TMEM16A overexpression reverted the suppressive effects of miR-381 overexpression on the migration
and invasion of gastric cancer cells**P < 0.01. d, e TMEM16A-overexpressing did not reverse the inhibition of gastric cancer cell proliferation induced
by the miR-381 overexpression
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[51–54]. Further investigations are needed to explore
the regulation of miR-381 in the furture.
TMEM16A, a potential oncogene, was found to be
amplified as part of human chromosome 11q13 ampli-
con, which may be one reason for TMEM16A overex-
pression [55, 56]. Our previous results showed that
TMEM16A overexpression was more pervasive than
amplification in gastric cancer [31], suggesting that
overexpression of TMEM16A in gastric cancer may
have any other regulatory mechanisms. To date, the
regulation of TMEM16A remains largely unknown. In
prostate cells, Cha et al. [57] found that the promoter
region of TMEM16A contains putative binding sites for
an androgen response element (ARE), which allow
testosterone-induced TMEM16A overexpression. Signal
transducer and activator of transcription 6 (STAT6)
binding site was also found in TMEM16A promoter re-
gion, leading to IL-4-induced TMEM16A up-regulation
[58]. In addition, epigenetic factors, such as methyla-
tion level of its promoter region [59], histone deacety-
lases (HDACs) [60], were reported to regulate the
expression of TMEM16A. Recent study revealed that
TMEM16A (ANO1) was a direct target gene of miR-
132, and was negatively regulated by miR-132 in colo-
rectal cancer [32]. One given gene might be regulated
by multiple miRNAs, while one given miRNA could
have various target genes [61, 62]. Consistently, in the
present study, we found that miR-381 directly targeted
3′UTR of TMEM16A and negatively modulated the
expression of TMEM16A in gastric cancer, moreover,
enforced overexpression of TMEM16A effectively re-
versed the tumor suppressive functions of miR-381 on
gastric cancer migration and invasion. These results
confirmed that miR-381 was one of the upstream regu-
lators of TMEM16A and by which exerted its suppres-
sive role in gastric cancer.
Our previous study found that TMEM16A facilitated
gastric cancer invasion and migration through suppressing
E-Cadherin expression via promoting TGF-β secretion
[31]. TGF-β was the most potent and most well-described
inducer for EMT [36]. After identifying TMEM16A was a
direct target of miR-381, our studies further showed that
miR-381 abolished TGF-β synthesis and secretion, and
subsequently down-regulated the expression of EMT
phenotype. Indeed, several signaling pathways were re-
ported to be involved in the functional role of miR-381. In
epithelial ovarian cancer, miR-381 targeted YY1 and regu-
lated p53 and Wnt signaling [12]. In glioma, miR-381 in-
creased the proliferation of tumor cells by targeting
LRRC4 and this action is associated with inducing MEK/
ERK and AKT signaling [18]. Inhibition of miR-381 sensi-
tized glioblastoma cells to temozolomide (TMZ) by
inhibiting the mTOR pathway through targeting NEFL
[63]. In addition, miR-381 contributed to respiratory infec-
tion through increasing the activity of NF-κB signaling by
directly targeting IκBα [64]. These studies indicated the
complicated role and mechanism of miR-381 depending
on different cancer types and molecular targets. In the
present study, miR-381 did not only influence the secre-
tion but also the synthesis of TGF-β, suggesting that other
molecules or pathways than targeting TMEM16A were
involved in the influence of miR-381 on TGF-β. Our data
also found that miR-381 could impair the expression of
EMT phenotype through miR-381/TMEM16A/TGF-β
axis. However, other pathways by which miR-381 regu-
lated EMT have been reported. For instance, Twist, an
important inducer of EMT, was found to be directly tar-
geted by miR-381 [14]. The underlying mechanism linking
miR-381 and EMT should be further investigated (Fig. 7).
(See figure on previous page.)
Fig. 6 Mir-381 suppresses TGF-β signaling pathway and down-regulated EMT phenotypes. Gastric cancer cells tranfected with anomiR-381 and
negative control, together with blank vector or TMEM16A overexpression plasmid. a ELISA assay indicated that supernatant concentrations of
TGF-β1 and TGF-β2 dramatically reduced in agomiR-381 group, and overexpression of TMEM16A could partially rescue their expression. **P < 0.01.
b QRT-PCR assay showed that mRNA of TGF-βs decreased in agomiR-381 group, which not be affected by overexpression of TMEM16A. c Protein
expression of TGF-β1 and TGF-β2 in gastric cancer cells down-regulated in miR-381 overexpression group, and further decreased in TMEM16A
overexpression group. d, e Transwell assay showed that the effect of miR-381 on gastric cancer cells migration and invasion could be partially
recovered by supplement of TGF-β. **P < 0.01. f Western blot assay was employed to detect the expression of EMT related markers in gastric
cancer cells
Fig. 7 Model for miR-381-mediated inhibition of cell proliferation
and migration via its regulation of the TMEM16A and TGF-β
signaling pathway. CDS coding sequence, 3′UTR 3′-untranslated
region, EMT epithelial-mesenchymal transition
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Conclusions
In this study, we finds for the first time that miR-381 is
decreased in gastric cancer and its down-regulation is aso-
ciated with poor clinical features of gastric cancer patients.
In vitro and in vivo experiments demonstrated that miR-
381 impedes gastric cancer proliferative and metastatic
behaviors. Mechanistically, we confirm that miR-381 sup-
pressed invasion and migration and EMT of gastric cancer
cells by targeting TMEM16A partially through TGF-β sig-
naling pathway (Fig. 7). Collectively, miR-381 may serve
as a novel therapeutic target for treating gastric cancer.
Additional files
Additional file 1: Figure S1. Confirmation of miR-381 overexpression in
gastric cancer cells. QRT-PCR analysis of miR-381 transfection efficiency
after agomiR-381 and negative control transfection in AGS and BGC-823
cell lines. (TIF 31 kb)
Additional file 2: Figure S2. Confirmation of miR-381 low-expression in
gastric cancer cells. QRT-PCR analysis of miR-381 transfection efficiency
after antagomiR-381 and negative control transfection in MKN-28 and
SGC-7901 cell lines. (TIF 29 kb)
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